# Mckesson Moat

Status: published. Policy: company-analysis-1.

McKesson has substantial distribution infrastructure, joint sourcing and integrated pharmacy services, but the supplied passages do not establish durable cost superiority, material switching barriers or network effects. Continued customer demand and strong pharmaceutical execution coexist with declining Health Mart participation and powerful counterparties. Observed supplier-linked pricing and less favorable customer renewals indicate constrained pricing discretion. Insufficient structural evidence, rather than demonstrated company-wide competitive weakness, supports the uncertain verdict.

## cost_advantage

The existing distribution network and joint generic sourcing provide credible operating scale, but relative procurement savings, delivery costs and barriers to replication are not demonstrated.

Durability: The infrastructure is established; management's claim that scale provides competitive advantage remains unquantified. The passages cannot establish a durable cost lead.

Risks: Supplier concentration limits negotiating power, customers have greater price bargaining power, and customers or manufacturers can develop internal supply capabilities.

Invalidation: The cost-advantage hypothesis would be undermined by comparable providers matching delivered costs and reliability, persistent deterioration in procurement terms, or major customers internalizing distribution without meaningful service or cost penalties.

Competitors: Not established
## switching_costs

Ordering, inventory and reconciliation services embed McKesson in customer workflows, and the CVS partnership extension demonstrates continuity. Material customer switching costs remain a hypothesis rather than a demonstrated advantage.

Durability: The disclosed CVS extension runs to June 2027. No migration costs, exclusive commitments or quantified dependence establish protection beyond existing relationships.

Risks: Customers sometimes reduce purchases, fail to renew or renew on less favorable terms. Health Mart participation fell from approximately 4,500 pharmacies in fiscal 2024 to 3,900 in fiscal 2026; the reasons are not disclosed.

Invalidation: The switching-cost hypothesis would be undermined by important customers replacing integrated services with little disruption, repeated non-renewals, or continued participation losses despite competitive service and pricing.

Competitors: Not established
- [https://www.sec.gov/Archives/edgar/data/927653/000092765326000069/mck-20260331.htm](https://www.sec.gov/Archives/edgar/data/927653/000092765326000069/mck-20260331.htm) · 2026-05-08
- [https://www.sec.gov/Archives/edgar/data/927653/000092765326000234/mck-20260630.htm](https://www.sec.gov/Archives/edgar/data/927653/000092765326000234/mck-20260630.htm) · 2026-08-05
- [https://www.sec.gov/Archives/edgar/data/927653/000092765326000169/mck-20260612.htm](https://www.sec.gov/Archives/edgar/data/927653/000092765326000169/mck-20260612.htm) · 2026-06-12
- [https://www.sec.gov/Archives/edgar/data/927653/000092765325000036/mck-20250331.htm](https://www.sec.gov/Archives/edgar/data/927653/000092765325000036/mck-20250331.htm) · 2025-05-09
- [https://www.sec.gov/Archives/edgar/data/927653/000092765324000035/mck-20240331.htm](https://www.sec.gov/Archives/edgar/data/927653/000092765324000035/mck-20240331.htm) · 2024-05-08
- [https://www.sec.gov/Archives/edgar/data/927653/000092765326000017/mck-20251231.htm](https://www.sec.gov/Archives/edgar/data/927653/000092765326000017/mck-20251231.htm) · 2026-02-04
- [https://www.sec.gov/Archives/edgar/data/927653/000092765326000253/ex991pressreleaseoctober62.htm](https://www.sec.gov/Archives/edgar/data/927653/000092765326000253/ex991pressreleaseoctober62.htm) · 2026-10-06
- [https://www.sec.gov/Archives/edgar/data/927653/000092765326000232/mck_exhibit991x6302026.htm](https://www.sec.gov/Archives/edgar/data/927653/000092765326000232/mck_exhibit991x6302026.htm) · 2026-08-05

[JSON](https://beanvest.com/stock/mck/moat.json)